Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IMVT Stock Alerts $28.61 -0.13 (-0.45%) (As of 04:29 PM ET) Add Compare Share Share Today's Range$28.54▼$29.7850-Day Range$28.22▼$38.3652-Week Range$15.39▼$45.58Volume1.06 million shsAverage Volume1.23 million shsMarket Capitalization$4.16 billionP/E RatioN/ADividend YieldN/APrice Target$48.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunovant alerts: Email Address Immunovant MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.8% Upside$48.00 Price TargetShort InterestBearish14.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 12 Articles This WeekInsider TradingSelling Shares$2.24 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.70) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.61 out of 5 starsMedical Sector442nd out of 910 stocksBiological Products, Except Diagnostic Industry65th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.92% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Immunovant has recently decreased by 3.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 2.4 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Immunovant this week, compared to 4 articles on an average week.Search Interest21 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,235,935.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.70) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -15.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -15.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 10.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Immunovant Stock (NASDAQ:IMVT)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More IMVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesApril 21, 2024 | insidertrades.comJulia G. Butchko Sells 10,115 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockApril 11, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) Insider Julia G. Butchko Sells 1,053 SharesApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy ConfidenceApril 21, 2024 | americanbankingnews.comEva Renee Barnett Sells 12,253 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockApril 21, 2024 | americanbankingnews.comPeter Salzmann Sells 34,079 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockApril 20, 2024 | investing.comImmunovant CFO sells shares worth over $350kApril 16, 2024 | finance.yahoo.comImmunovant, Inc. (IMVT) Stock Historical Prices & Data - Yahoo FinanceApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 15, 2024 | nasdaq.comImmunovant is Now Oversold (IMVT)April 13, 2024 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by BrokeragesApril 12, 2024 | investing.comImmunovant CEO sells over $149,000 in company stockApril 4, 2024 | seekingalpha.comImmunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)March 25, 2024 | investorplace.comWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichMarch 22, 2024 | markets.businessinsider.comBuy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab TrialsMarch 12, 2024 | finanznachrichten.deImmunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402March 12, 2024 | globenewswire.comImmunovant Awarded U.S. Patent for IMVT-1402March 11, 2024 | finance.yahoo.comIMVT Jul 2024 30.000 callMarch 11, 2024 | finance.yahoo.comIMVT Mar 2024 40.000 callMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 32.000 callMarch 10, 2024 | finance.yahoo.comIMVT Apr 2024 45.000 putMarch 10, 2024 | finance.yahoo.comIMVT Jan 2025 12.500 putMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 29.000 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.500 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.000 callMarch 6, 2024 | finance.yahoo.comIMVT Mar 2024 32.000 putMarch 5, 2024 | finance.yahoo.comIMVT Mar 2024 33.000 putSee More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today4/23/2024Next Earnings (Estimated)5/27/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$48.00 High Stock Price Target$57.00 Low Stock Price Target$32.00 Potential Upside/Downside+67.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.97% Return on Assets-52.47% Debt Debt-to-Equity RatioN/A Current Ratio22.14 Quick Ratio22.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book10.29Miscellaneous Outstanding Shares145,290,000Free Float138,319,000Market Cap$4.16 billion OptionableOptionable Beta0.65 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 45)M.D., Executive Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 44)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 61)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., Vice President of Investor RelationsMr. Mark S. Levine (Age 51)Chief Legal Officer & Corporate Secretary Ms. Lauren Schrier M.B.A.Vice President of MarketingMs. Christine BlodgettVice President of Human ResourcesDr. Julia G. Butchko Ph.D. (Age 53)Chief Development Officer Comp: $531kMore ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPImmunityBioNASDAQ:IBRXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 22,226 shares on 4/18/2024Ownership: 0.045%Peter SalzmannSold 34,079 sharesTotal: $990,335.74 ($29.06/share)Julia G ButchkoSold 10,115 sharesTotal: $293,941.90 ($29.06/share)Eva Renee BarnettSold 12,253 sharesTotal: $356,072.18 ($29.06/share)Peter SalzmannSold 4,807 sharesTotal: $149,882.26 ($31.18/share)View All Insider TransactionsView All Institutional Transactions IMVT Stock Analysis - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price target for 2024? 17 Wall Street analysts have issued 1 year price targets for Immunovant's shares. Their IMVT share price targets range from $32.00 to $57.00. On average, they expect the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 67.8% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2024? Immunovant's stock was trading at $42.13 at the beginning of the year. Since then, IMVT stock has decreased by 32.1% and is now trading at $28.61. View the best growth stocks for 2024 here. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). Who are Immunovant's major shareholders? Immunovant's stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMVT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
